{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:34:59Z","timestamp":1791329699070,"version":"4.3.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0190425","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T13:53:08Z","timestamp":1515419588000},"page":"e0190425","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-5237","authenticated-orcid":true,"given":"Anza B.","family":"Memon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Caon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitiz","family":"Srivastawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Bernitsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Chorostecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Tselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Seraji-Bozorgzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"J.E. Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"For the OPERA, I and OPERA II Clinical Investigators* Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"SL Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"L.M. Nadler","year":"1981","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"P. Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"P.M. Cardarelli","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"G. Cartron","year":"2004","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"M.C. Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"E.G. Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"M.J. Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"S.L. Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"A. Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"R.J. Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"K. Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"D.B. Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000368072","article-title":"Progressive multifocal leukoencephalopathy in patients with a hematological malignancy: review of therapeutic options","volume":"60","author":"A. Kalisch","year":"2014","journal-title":"Chemotherapy"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","article-title":"Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?","volume":"8","author":"E.S. Molloy","year":"2008","journal-title":"Autoimmune Rev"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"RF Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"R.C. Dale","year":"2014","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study","volume":"82","author":"P.S. Sorensen","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"SH Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"20","key":"ref21","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"J Salzer","year":"2016","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"E.F. Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"W. Rigby","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"L. Kappos","year":"2011","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"for the ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"X. Montalban","year":"2017","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0190425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:23:05Z","timestamp":1540218185000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0190425"}},"subtitle":[],"editor":[{"given":"Martin Sebastian","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0190425","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}